Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Lexicon Pharmaceuticals Inc. oversees a company patent portfolio in the Biotechnology & Pharmaceuticals sector. The portfolio includes 4 pending office actions. These actions are handled by 4 distinct examiners, ensuring a variety of perspectives on the company's pharmaceutical claims. The pending office actions are situated within 2 distinct art units. HASTINGS, ALISON AZAR is the busiest examiner with 1 pending action. The presence of 4 pending actions indicates a focused prosecution stage for the company.
The concentration in 2 art units, despite having 4 distinct examiners, indicates that multiple examiners are working within the same technical groups. Practitioners should prepare for separate examiner interactions across the identified art units. This structure allows the company to engage with multiple officials who likely share a similar technical background. Managing the 1 pending action with the busiest examiner requires coordination with the other 4 distinct examiners involved in the portfolio. This approach ensures that each of the 4 pending office actions receives an independent review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | CRAIGO, BAHAR ALAWI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | HASTINGS, ALISON AZAR | — |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | HASTINGS, ALISON AZAR | — | DP | Non-Final OA | — | Pending | Apr 28, 2025 |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | — | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | CRAIGO, BAHAR ALAWI | 1699 | §101§102§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 17631209 | PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF SOTAGLIFLOZIN | BERRY, LAYLA D | 1693 | §112Other | Non-Final OA | 53d | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial